Add Yahoo as a preferred source to see more of our stories on Google. Patients with advanced bladder cancer have significantly less risk of the disease progressing or returning when treated with an ...
May 14 (Reuters) - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to ...
AstraZeneca PLC AZN on Thursday said interim results from the Phase 3 VOLGA trial showed that perioperative treatment with ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and ...
High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) ...
TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Individuals presenting with repeated UTIs experience longer diagnostic delays and poorer outcomes than those presenting with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results